Papers
Topics
Authors
Recent
Search
2000 character limit reached

An evolutionary model of tumor cell kinetics and the emergence of molecular heterogeneity driving Gompertzian growth

Published 14 Dec 2015 in q-bio.PE | (1512.04590v4)

Abstract: A cell-molecular based evolutionary model of tumor development driven by a stochastic Moran birth-death process is developed, where each cell carries molecular information represented by a four-digit binary string, used to differentiate cells into 16 molecular types. The binary string value determines cell fitness, with lower fit cells (e.g. 0000) defined as healthy phenotypes, and higher fit cells (e.g. 1111) defined as malignant phenotypes. At each step of the birth-death process, the two phenotypic sub-populations compete in a prisoner's dilemma evolutionary game with healthy cells (cooperators) competing with cancer cells (defectors). Fitness and birth-death rates are defined via the prisoner's dilemma payoff matrix. Cells are able undergo two types of stochastic point mutations passed to the daughter cell's binary string during birth: passenger mutations (conferring no fitness advantage) and driver mutations (increasing cell fitness). Dynamic phylogenetic trees show clonal expansions of cancer cell sub-populations from an initial malignant cell. The tumor growth equation states that the growth rate is proportional to the logarithm of cellular heterogeneity, here measured using the Shannon entropy of the distribution of binary sequences in the tumor cell population. Nonconstant tumor growth rates, (exponential growth during sub-clinical range of the tumor and subsequent slowed growth during tumor saturation) are associated with a Gompertzian growth curve, an emergent feature of the model explained here using simple statistical mechanics principles related to the degree of functional coupling of the cell states. Dosing strategies at early stage development, mid-stage (clinical stage), and late stage development of the tumor are compared, showing therapy is most effective during the sub-clinical stage, before the cancer subpopulation is selected for growth.

Summary

No one has generated a summary of this paper yet.

Paper to Video (Beta)

No one has generated a video about this paper yet.

Whiteboard

No one has generated a whiteboard explanation for this paper yet.

Open Problems

We haven't generated a list of open problems mentioned in this paper yet.

Continue Learning

We haven't generated follow-up questions for this paper yet.

Collections

Sign up for free to add this paper to one or more collections.